LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Purchased by Asset Management One Co. Ltd.

Asset Management One Co. Ltd. increased its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 133.4% in the 4th quarter, HoldingsChannel reports. The firm owned 2,229 shares of the medical instruments supplier’s stock after purchasing an additional 1,274 shares during the period. Asset Management One Co. Ltd.’s holdings in LeMaitre Vascular were worth $207,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. KBC Group NV grew its stake in LeMaitre Vascular by 58.4% during the 4th quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier’s stock worth $102,000 after purchasing an additional 410 shares in the last quarter. Empowered Funds LLC purchased a new stake in LeMaitre Vascular during the 4th quarter worth about $150,000. SG Americas Securities LLC purchased a new stake in LeMaitre Vascular during the 4th quarter worth about $158,000. Advisors Asset Management Inc. lifted its holdings in LeMaitre Vascular by 180.2% during the 3rd quarter. Advisors Asset Management Inc. now owns 1,852 shares of the medical instruments supplier’s stock worth $172,000 after buying an additional 1,191 shares during the last quarter. Finally, Sanctuary Advisors LLC purchased a new stake in LeMaitre Vascular during the 3rd quarter worth about $181,000. 84.64% of the stock is owned by institutional investors and hedge funds.

LeMaitre Vascular Stock Down 2.2 %

LMAT opened at $100.92 on Friday. The business has a 50 day moving average price of $96.05 and a two-hundred day moving average price of $93.97. The company has a market cap of $2.27 billion, a PE ratio of 55.15, a P/E/G ratio of 2.21 and a beta of 0.96. LeMaitre Vascular, Inc. has a 52 week low of $59.87 and a 52 week high of $109.58.

Analyst Ratings Changes

A number of brokerages have issued reports on LMAT. StockNews.com downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Barrington Research lifted their price target on LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a report on Friday, November 1st. Wells Fargo & Company began coverage on LeMaitre Vascular in a report on Thursday, February 13th. They set an “equal weight” rating and a $95.00 price target for the company. Finally, Oppenheimer reissued an “outperform” rating and issued a $93.00 target price (up from $90.00) on shares of LeMaitre Vascular in a report on Friday, November 1st. Three investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, LeMaitre Vascular currently has a consensus rating of “Moderate Buy” and an average price target of $94.63.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.